Senseonics Stock Price, News & Analysis

Senseonics Holdings, Inc. (NYSE American: SENS) has granted equity awards to 13 new non-executive employees under its 2019 Inducement Plan. On April 4, 2023, the Compensation Committee approved non-qualified stock options for 200,000 shares and restricted stock units for 250,000 shares, with an exercise price of $0.5951 per share. The options and units will vest over time, contingent on continuous employment. Senseonics focuses on developing innovative long-term implantable glucose monitoring systems aimed at improving diabetes management.

Senseonics Holdings, Inc. (SENS) reported financial results for Q4 and full year 2022, revealing a total revenue of $16.4 million for 2022, up from $13.7 million in 2021. Notably, Q4 2022 revenue reached $5.6 million, marking a rise from $4.0 million in Q4 2021. Gross profit for the full year was $2.7 million, a significant improvement from a gross loss of $0.8 million. The company achieved a net income of $142.1 million in 2022, compared to a net loss of $302.5 million the previous year. Senseonics also anticipates revenue growth for 2023, projecting a range of $20 million to $24 million, indicating an increase of 22% to 46% compared to 2022.

Senseonics (AMEX:SENS) will release its fourth quarter and full year 2022 financial results after market close on March 15, 2023. A joint virtual event with PHC Holdings and Ascensia Diabetes Care will take place on the same day at 6:30 pm ET, featuring presentations from executives including Tim Goodnow and Rick Sullivan. They will discuss the Eversense technology portfolio, commercial partnerships, and provide financial guidance. The webcast will be accessible on Senseonics' website under “Investor Relations” for future reference.

Senseonics Holdings, Inc. (NYSE American: SENS) announced it granted equity to 10 new non-executive employees under its 2019 Inducement Plan. On January 5, 2023, the Compensation Committee awarded non-qualified stock options totaling 115,000 shares at an exercise price of $1.02, reflecting the closing share price on the grant date. The options will vest 25% on the first anniversary of employment and monthly thereafter over three years, contingent on continued service. Senseonics specializes in long-term implantable continuous glucose monitoring systems for diabetes management.

Senseonics Holdings, Inc. (SENS), a leader in long-term implantable continuous glucose monitoring systems, has announced their participation in the Stifel Healthcare Conference in New York, NY. Scheduled for Tuesday, November 15, 2022, at 11:30am ET, management will engage in one-on-one meetings post-presentation. A live and recorded webcast will be accessible through a provided link.

Senseonics aims to enhance the lives of those with diabetes through its innovative glucose management technology, including the Eversense CGM system that continuously transmits glucose data to users' mobile devices.

Senseonics Holdings, Inc. (NYSE American: SENS) reported its financial results for the quarter ended September 30, 2022, generating $4.6 million in revenue, up from $3.5 million in Q3 2021. U.S. revenue rose to $1.9 million, while international revenue saw a decline to $2.7 million. The company experienced a net loss of $60.4 million compared to a net income of $42.9 million in the previous year, largely due to non-cash accounting adjustments. Senseonics updated its full-year revenue outlook to $15.0 million to $17.0 million from a previous range of $14.0 million to $18.0 million.

Senseonics Holdings, Inc. (SENS) announces its collaboration with the Nurse Practitioner Group (NPG) to enhance access to the Eversense® E3 Continuous Glucose Monitoring (CGM) System. The initiative aims to provide convenient at-home and in-office insertion options for diabetes patients. The first Eversense E3 sensor was successfully inserted in Florida, with plans for expansion across the U.S. This partnership will facilitate certified NPG providers to perform Eversense procedures, thereby broadening clinician reach and improving patient experiences.

Senseonics Holdings, Inc. (NYSE American: SENS) has announced it will release its third quarter 2022 financial results after market close on November 8, 2022. The management will host a conference call at 4:30 p.m. ET on the same day to discuss the company's performance. Senseonics focuses on long-term, implantable continuous glucose monitoring (CGM) systems aimed at the diabetes community, with products like Eversense® and Eversense® XL providing real-time glucose data through a small sensor under the skin.

Senseonics Holdings, Inc. (NYSE American: SENS) announced participation in the upcoming Morgan Stanley Global Healthcare Conference in New York. On October 5, 2022, the company granted 6 non-executive employees stock options for a total of 78,000 shares at an exercise price of $1.34, contingent on continued service and vesting after one year. Senseonics aims to expand its Eversense CGM System availability and enhance the product, which continuously measures glucose levels for up to 6 months, providing an alternative to traditional fingerstick tests.